Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.

Puerto Rico health sciences journal - 1 Sept 2014

Valentín Isa I, Rivera Giselle, Nieves-Plaza Mariely, Cruz Iadelisse, Renta Jessica Y, Cadilla Carmen L, Feliu Juan F, Seip Richard L, Ruaño Gualberto, Duconge Jorge

Abstract excerpt

OBJECTIVE: This study was intended to determine the incidence rate of warfarin-related adverse events (e.g., bleeding) in Puerto Ricans and whether a genetic association between warfarin pharmacogenes and any of these adverse events was observed over the initiation period (i.e., the first 90 days of therapy). METHODS: We conducted an observational, retrospective cohort study of pharmacogenetic association in 122...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticoagulants

Share to Cohort Studies

Share to Genotype

Share to Hemorrhage

Share to Puerto Rico

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 25244877
PMCID: PMC4196861

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.PMID 25244877Read ↗

Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Semantic proximity Read ↗

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Semantic proximity Read ↗

Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.Semantic proximity Read ↗

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.Semantic proximity Read ↗

Pharmacogenetics of warfarin: current status and future challenges.Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.Semantic proximity Read ↗

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.Semantic proximity Read ↗

New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model.Semantic proximity Read ↗

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.Semantic proximity Read ↗

The pharmocogenomics of warfarin: closing in on personalized medicine.Semantic proximity Read ↗

Warfarin pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.